Polycystic ovary syndrome is diagnosed through a combination of clinical signs, hormone levels, and imaging findings rather than any single blood test. The most widely used framework looks for at least two of three features: excess androgen activity, irregular or absent ovulation, and a characteristic appearance of the ovaries on ultrasound. But the picture is more complicated than that tidy checklist suggests, because dozens of blood-based and imaging-based markers now inform how clinicians detect, classify, and monitor the condition, and newer markers from metabolomics and genetics are beginning to reshape the landscape.
How PCOS Gets Diagnosed Today
The dominant diagnostic framework since 2003 has been the Rotterdam criteria, which require two out of three features: clinical or biochemical hyperandrogenism, oligo-ovulation or anovulation, and polycystic ovarian morphology on ultrasound. This “two-out-of-three” approach creates four possible phenotypes, and the wide range of symptom combinations is a major reason PCOS remains underdiagnosed or misdiagnosed for years in many women.1Europe PMC / Diagnostics. Current Guidelines for Diagnosing PCOS No single marker confirms PCOS on its own. Instead, clinicians build a case from multiple markers while actively ruling out other conditions that mimic the syndrome.
Androgen Markers and Why They Are Central
Hyperandrogenism, whether visible as acne, excess hair growth, or scalp thinning, or detectable only through blood work, is the feature most closely tied to the syndrome’s underlying biology. Total testosterone is the most commonly ordered test, but it is far from the most sensitive. Free testosterone and the free androgen index (FAI) have been shown to be stronger predictors of PCOS than total testosterone alone.2Clinica Chimica Acta. Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome The reason is straightforward: much of the testosterone circulating in your blood is bound to a carrier protein called sex hormone-binding globulin (SHBG), which keeps it inactive. Only the unbound fraction is biologically active. A woman can have a “normal” total testosterone reading while the free, active portion is elevated because her SHBG is low.
SHBG itself doubles as a metabolic marker. Low levels are associated with insulin resistance, abnormal glucose and lipid metabolism, and higher androgen activity, making it one of the more informative single blood tests in a PCOS workup.3PubMed Central. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment When SHBG drops, more testosterone becomes free, and the metabolic environment often worsens in tandem. Clinicians who only check total testosterone without measuring SHBG or calculating the free androgen index risk missing the biochemical picture entirely.
11-Oxyandrogens and the Adrenal Angle
Standard androgen panels focus on testosterone and androstenedione, both of which come primarily from the ovaries. But the adrenal glands produce their own class of androgens, the 11-oxygenated androgens (sometimes called 11-oxyandrogens), which have emerged over the past decade as significant contributors to androgen excess in PCOS.4PubMed Central. 11-Oxygenated androgens in health and disease These are not yet part of routine clinical panels, but research suggests they add real diagnostic value. In one study, when all androgens were evaluated individually, 11-ketoandrostenedione was the single most predictive marker of PCOS, and the group of four 11-oxyandrogens together outperformed testosterone and androstenedione as predictors.5PubMed Central. Exploring the Predictive Role of 11-Oxyandrogens in Diagnosing Polycystic Ovary Syndrome This matters clinically because some women with PCOS have normal-looking conventional androgen tests while harboring elevated 11-oxyandrogens that standard panels miss.
The LH-to-FSH Ratio
An elevated ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH) was once considered a hallmark of PCOS. The idea was intuitive: LH drives androgen production in the ovaries, while FSH drives follicle maturation, so a skewed ratio would explain both the androgen excess and the failure of follicles to fully develop. The ratio does tend to be elevated in many women with PCOS, and some studies report average values above 2:1.6PubMed Central. Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) – Obese vs. Non-Obese Women But it is no longer considered a reliable standalone diagnostic marker, because the ratio fluctuates with the menstrual cycle, varies with body weight, and is normal in a substantial fraction of women who meet other PCOS criteria.
More recent work has focused on what drives the elevated ratio in lean women with PCOS, finding that anti-Müllerian hormone (AMH) levels and certain neuropeptides like dynorphin have significant relationships with the LH-to-FSH ratio in this subgroup.7Scientific Reports. Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis The ratio remains a useful clue, especially when it is clearly high, but clinicians now treat it as one piece of a larger puzzle rather than a definitive marker.
Anti-Müllerian Hormone as a Surrogate for Ovarian Morphology
AMH is produced by the small growing follicles in the ovaries, and women with PCOS tend to have far more of these follicles than average. Research has consistently shown that AMH levels run at least two to three times higher in women with PCOS compared to controls, and those levels track closely with the number of follicles visible on ultrasound.8PubMed Central. Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress This has led to growing interest in using AMH as a blood-test substitute for transvaginal ultrasound, particularly in settings where ultrasound is unavailable or impractical.
AMH is especially valuable in two populations where ultrasound-based diagnosis is unreliable: adolescents and people who have not had vaginal examinations. The 2023 international evidence-based guideline for PCOS now recognizes AMH as an alternative to ultrasound for the polycystic ovary criterion in adults. Still, standardization remains a challenge. AMH assays vary across laboratories, and universally agreed-upon cutoff values have not been finalized, so the result needs to be interpreted carefully alongside other markers.
Ultrasound Findings and the Moving Target of Follicle Counts
The classic ultrasound finding in PCOS is polycystic ovarian morphology: multiple small follicles arranged around the periphery of an enlarged ovary. For years, the threshold was 12 or more follicles per ovary, set back when ultrasound technology was lower resolution. With modern machines that can resolve smaller follicles, healthy women often cross that old threshold. Updated research using high-resolution ultrasound found that a threshold of 26 follicles per ovary provided the best balance of sensitivity and specificity for distinguishing PCOS from healthy controls, with about 85% sensitivity and 94% specificity. An ovarian volume above 10 cubic centimeters was also discriminating, though with somewhat lower accuracy.9Human Reproduction. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume
This shift from 12 to 26 follicles matters practically. If your ultrasound report shows 15 or 18 follicles per ovary and your clinician uses the older threshold, you might be told you have polycystic morphology when a more current interpretation would say you fall within normal range. When reviewing imaging results, it helps to ask which threshold your provider is using.
Metabolic Markers and Insulin Resistance
Insulin resistance is not part of the formal Rotterdam diagnostic criteria, but it runs through much of PCOS biology like a common thread. Excess insulin stimulates androgen production in the ovaries and suppresses SHBG in the liver, feeding the hormonal imbalance from the metabolic side. Testing for insulin resistance is recommended as part of the broader workup, especially because early detection opens the door to interventions that reduce long-term risk of type 2 diabetes and cardiovascular disease.
The challenge is that measuring insulin resistance is surprisingly method-dependent. The most commonly used clinical tool, HOMA-IR, calculates a score from fasting glucose and fasting insulin. But studies in women with PCOS have shown that HOMA-IR catches fewer cases of insulin resistance than methods based on an oral glucose tolerance test. In one study, the Belfiore insulin resistance index flagged about half of PCOS participants as insulin resistant, while HOMA-IR identified only about a quarter of them, depending on the cutoff used.10PubMed Central. How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models The practical takeaway: a normal HOMA-IR does not necessarily rule out insulin resistance in PCOS. If there is strong clinical suspicion, a glucose tolerance test with insulin levels drawn at intervals gives a more complete picture.
Beyond insulin itself, fasting glucose, HbA1c, and a full lipid panel round out the metabolic assessment. The adiponectin-to-leptin ratio has also drawn attention as a marker linking insulin resistance and chronic low-grade inflammation; in women with PCOS, this ratio correlates with insulin resistance indexes and with C-reactive protein independently of body mass index.11PubMed. The adiponectin-to-leptin ratio in women with polycystic ovary syndrome: relation to insulin resistance and proinflammatory markers It is not a routine clinical test, but it illustrates how fat-tissue hormones interact with the rest of the PCOS picture.
Inflammatory Markers
Chronic low-grade inflammation is increasingly recognized as part of the PCOS profile, though whether it is a cause, a consequence, or both remains debated. High-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-alpha (TNF-α) are the markers studied most often. One study using multiple inflammatory markers found that platelet microparticles, hs-CRP, and TNF-α were all significantly higher in women with PCOS compared to controls, while interleukin-6 did not differ between the groups.12PubMed Central. Chronic inflammation in polycystic ovary syndrome: A case–control study using multiple markers
The relationship between inflammation and body weight complicates interpretation. When women with PCOS were divided by BMI, those who were lean showed no significant difference in hs-CRP, IL-6, or TNF-α compared to weight-matched healthy controls, while those with higher BMI did show elevated inflammatory markers.13PubMed Central. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index This suggests that at least part of the inflammatory signal in PCOS tracks with excess weight and insulin resistance rather than the syndrome itself. Inflammatory markers are not used diagnostically, but they can help stratify cardiovascular and metabolic risk, especially in women with PCOS who also have obesity or insulin resistance.
What Has to Be Ruled Out First
PCOS is a diagnosis of exclusion in the sense that several other conditions share its features and must be checked for before the label is applied. The Endocrine Society’s clinical practice guideline specifies that evaluation should exclude alternate androgen-excess disorders as well as risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease.14PubMed Central. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline In practice, this means your workup will often include thyroid-stimulating hormone (TSH) to check for thyroid dysfunction, prolactin to rule out a prolactin-secreting pituitary issue, and 17-hydroxyprogesterone to screen for non-classic congenital adrenal hyperplasia. In some cases, overnight dexamethasone suppression or 24-hour urinary cortisol may be ordered to exclude Cushing syndrome. These are not “PCOS markers” in the strict sense, but they are routine parts of the blood panel that leads to a PCOS diagnosis.
Why Diagnosing PCOS in Adolescents Is Different
Irregular periods and acne are so common during the first few years after a girl’s first period that applying adult PCOS criteria to teenagers risks massive overdiagnosis. Polycystic ovarian morphology on ultrasound is particularly unreliable in this age group, because many healthy adolescents have ovaries that look polycystic while their reproductive system is still maturing.15PubMed Central. Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review For this reason, current recommendations state that polycystic morphology on ultrasound should not be used as a diagnostic criterion in adolescents. The diagnosis instead rests on the combination of ovulatory dysfunction that persists beyond what is developmentally normal, and clear evidence of androgen excess, either clinical (moderate-to-severe hirsutism, persistent acne unresponsive to topical treatment) or biochemical (elevated free testosterone or total testosterone).16PubMed Central. Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies
AMH may eventually prove useful in teenagers as well, since it sidesteps the ultrasound problem, but age-specific cutoffs have not been validated well enough to use confidently. In borderline cases, many clinicians prefer to label the presentation as “at risk for PCOS” and reassess after a few years rather than commit to a lifelong diagnosis prematurely.
PCOS Markers After Menopause
Because PCOS is defined partly by menstrual irregularity and ovarian morphology, both of which naturally change with age, the question of whether PCOS “goes away” after menopause comes up frequently. Androgen levels do decline with age, and ovarian volume shrinks, which can make the condition harder to detect on conventional tests. But the metabolic consequences do not necessarily fade. PCOS is recognized as a major risk factor for type 2 diabetes and cardiovascular disease in later life, and these risks persist well beyond the reproductive years.17PubMed Central. Polycystic Ovarian Syndrome and Menopause in Forty Plus Women For postmenopausal women with a history of PCOS, metabolic markers like fasting insulin, glucose, lipid panels, and blood pressure monitoring become the primary tracking tools, even as hormonal markers lose their diagnostic utility.
Emerging Markers From Metabolomics, Genetics, and Epigenetics
The markers discussed so far are all used, to varying degrees, in current clinical practice. A wave of research is exploring markers that might eventually improve diagnosis, subtype classification, or risk prediction, though none has made it into routine use yet.
Metabolomic Signatures
Metabolomics, the large-scale study of small molecules in blood or other fluids, has revealed that women with PCOS show distinct shifts in amino acid, lipid, and carbohydrate metabolism. Levels of several amino acids including valine, phenylalanine, and tyrosine tend to be elevated, while glycine and proline are reduced. The ratio of branched-chain amino acids to aromatic amino acids was found to be significantly lower in PCOS samples, and this ratio held up regardless of obesity or insulin sensitivity.18PubMed Central. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis Separate work on subtyping showed that panels of metabolites could distinguish between PCOS patients with primarily hyperandrogenism versus primarily insulin resistance, with some biomarker panels achieving predictive accuracy above 90% in validation testing.19PubMed. Serum metabolomics reveals metabolic profiling for women with hyperandrogenism and insulin resistance in polycystic ovary syndrome If these metabolomic panels become standardized and affordable, they could help clinicians tailor treatment to a woman’s specific metabolic profile rather than treating PCOS as a monolithic condition.
MicroRNAs
MicroRNAs are tiny molecules that regulate gene activity, and several show altered levels in PCOS. A study measuring three specific microRNAs (miR-21, miR-222, and Let-7b) found that their combined signal in blood serum had a diagnostic area under the curve of 0.86, a reasonably strong discriminator between PCOS and non-PCOS.20Medical Journal Armed Forces India. Differential expression of miR-21, miR-222, and Let-7b in serum and follicular fluid of polycystic ovary syndrome: Correlation with biochemical parameters The same microRNAs performed much worse when measured in follicular fluid rather than blood, suggesting serum is the more useful sample type. MicroRNA testing is not available clinically for PCOS, but it represents one of the more promising avenues for a future blood-based diagnostic that does not depend on hormone levels or imaging.
Polygenic Risk Scores
Genome-wide association studies have identified dozens of genetic variants associated with PCOS risk. Individually, each variant contributes a tiny amount, but combined into a polygenic risk score, they begin to have meaningful predictive power. One large study found that integrating polygenic predictions with phenotypic data improved PCOS detection roughly 58- to 62-fold over a null model across European, African, and multi-ancestry populations.21The Journal of Clinical Endocrinology & Metabolism. A Polygenic and Phenotypic Risk Prediction for Polycystic Ovary Syndrome Evaluated by Phenome-Wide Association Studies The practical value of genetic risk scores lies less in diagnosing someone who already has symptoms and more in identifying high-risk individuals before the syndrome fully manifests, potentially enabling earlier lifestyle or medical intervention.
The Gut Microbiome and PCOS
A growing body of research has linked gut microbial composition to the hormonal and metabolic disturbances in PCOS. The gut microbiome is involved in regulating insulin secretion, androgen metabolism, and follicle development.22Europe PMC / Frontiers in Cellular and Infection Microbiology. Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications Women with PCOS tend to have reduced microbial diversity compared to controls, and certain bacterial genera appear consistently over- or under-represented. Whether these shifts are a cause or a downstream effect of the metabolic environment remains an open question, and no gut-microbiome-based diagnostic test exists for PCOS. But the connection opens up the possibility that interventions targeting the microbiome, such as specific probiotics or dietary changes, could eventually complement hormone-based and metabolic treatments.
Environmental Exposures as a Marker Layer
Endocrine-disrupting chemicals, particularly bisphenol A (BPA), have gained attention as potential contributors to PCOS pathology. A systematic review found that most studies reported significantly higher BPA levels in the blood, urine, or follicular fluid of women with PCOS. Higher BPA was positively correlated with insulin resistance, androgen levels, polycystic morphology on ultrasound, and markers of chronic inflammation, while it was negatively correlated with SHBG and markers of ovarian reserve.23PubMed Central. Polycystic Ovary Syndrome and Endocrine Disruptors (Bisphenols, Parabens, and Triclosan)—A Systematic Review BPA’s ability to bioaccumulate with daily exposure and activate hormonal signaling pathways could alter metabolic and reproductive function in ways that favor hyperandrogenism, insulin resistance, and anovulation.24PubMed Central. Does bisphenol A (BPA) participates in the pathogenesis of Polycystic Ovary Syndrome (PCOS)?
BPA levels are not measured as part of any clinical PCOS workup, and the associations do not prove causation. But the pattern is consistent enough that reducing exposure to endocrine disruptors, by choosing BPA-free food containers, avoiding heating plastics, and limiting contact with thermal receipt paper, is a reasonable precautionary step for anyone concerned about hormonal health. The research is still working out whether high BPA levels are a trigger, an accelerant, or simply a correlate of the metabolic environment that predisposes someone to PCOS.